H.C. Wainwright reiterates Mineralys stock rating at buy By Investing.com

H.C. Wainwright reiterated a Buy on Mineralys Therapeutics and kept its $56 price target, with the stock carrying a strong consensus recommendation of 1.2 and a 102% 1-year return. The firm highlighted favorable post hoc Launch-HTN data for lorundrostat, including statistically significant blood pressure reductions in chronic kidney disease patients and a consistent safety profile over 12 weeks, while the company also reported a Q1 2026 EPS beat of -$0.47 versus -$0.81 expected. Mineralys’ NDA acceptance and PDUFA date of December 22, 2026 add further clinical/regulatory support.

Analysis

The immediate market read-through is less about the sponsor’s clinical update and more about duration of the story: this is now a late-2026 regulatory asset with enough de-risking to support multiple expansion, but still far enough out that execution risk dominates. In practice, that means the stock should trade more like a binary pipeline optionality name than a pure fundamentals story; the next leg is likely to come from label-quality data, reimbursement confidence, or a financing event rather than the current hypertension signal itself.

The more interesting second-order effect is positioning. Investors tend to crowd into obesity and GLP-1 adjacencies in cardio-metabolic biotech, but a differentiated antihypertensive with kidney-disease relevance can attract a broader base of specialists if it keeps showing albuminuria benefit. That matters because renal-risk reduction can widen the commercial opportunity beyond blood-pressure management alone, increasing the probability of strategic interest from larger cardiovascular or nephrology-focused pharma if the dataset remains clean.

The main risk is that the current enthusiasm is front-running a thesis that still needs replication and commercial clarity. Any ambiguity around durability, safety in CKD, or the ultimate breadth of label could compress the multiple quickly, especially if the market rotates away from pre-revenue biotech or if the company needs additional capital before approval. Over the next 3-6 months, the stock is more sensitive to conference cadence and sell-side estimate revisions than to macro; over 12-18 months, the real catalyst stack is NDA progress, partner interest, and whether prescribers view the drug as additive versus simply another incremental BP option.

Key Decisions for Investors

• Long MLYS on pullbacks over the next 1-3 weeks; treat it as a catalyst-driven momentum trade with 20-30% upside if the market continues to re-rate renal-adjacent differentiation, but keep a tight 10-15% stop given binary biotech volatility.
• Buy MLYS Jan-2027 calls or call spreads to express the regulatory/partnering optionality while limiting downside; best structure is a moderate-delta spread to avoid paying up for implied volatility in a pre-approval name.
• Pair trade: long MLYS / short a basket of crowded cardio-metabolic biotech names with weaker differentiation; the relative trade should work if investors rotate from generic obesity exposure toward mechanistically distinct hypertension/renal assets.
• If MLYS rallies sharply into the next conference or investor event, consider monetizing into strength rather than adding; the near-term upside is data-sensitivity-driven, but the stock remains vulnerable to any change in safety or durability perception.
• Avoid sizing as a core long until there is clearer evidence of commercial breadth or strategic interest; otherwise the risk/reward is attractive only as a tactical, event-driven position rather than a permanent portfolio holding.